Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Amans

Neuroradiology San Francisco, CA Medical Doctor

NPI 1881845766 CMS profile 39728

505 Parnassus Ave, Room L-371, San Francisco, CA 94143

Open in the dashboard

General payments

$51,156

206 records reported · program years 2019–2025

Research payments

$1,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Amans of San Francisco, CA is reported in the CMS Open Payments database as having received $51,156 across 206 general payments and $1,200 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neuroradiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,006 39
2024 General $2,949 40
2023 General $3,138 21
2022 General $7,659 34
2021 General $11,124 22
2020 General $3,782 16
2019 General $16,497 34
2019 Research $1,200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Amans
  • Neuroradiology median
  • Middle half of Neuroradiology
  • National median

In program year 2025, general payments to Matthew Amans were reported at $6,006. Among 399 Neuroradiology profiles paid that year, the median was $279 and the middle half received between $65 and $2,205.

Show as a table
Year Matthew Amans Neuroradiology median Middle half National median
2019 $16,497 $288 $71–$2,035 $163
2020 $3,782 $165 $32–$1,794 $114
2021 $11,124 $238 $42–$1,807 $132
2022 $7,659 $191 $49–$1,388 $149
2023 $3,138 $228 $56–$1,148 $160
2024 $2,949 $241 $97–$2,192 $164
2025 $6,006 $279 $65–$2,205 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $26,071 144 payments
  2. Medtronic USA, Inc. $17,910 21 payments
  3. MicroVention, Inc. $6,058 18 payments
  4. Medtronic, Inc. $601 8 payments
  5. Penumbra, Inc. $168 8 payments
  6. Route 92 Medical, Inc. $142 1 payment
  7. Cardiva Medical, Inc. $55 1 payment
  8. Abbott Laboratories $48 2 payments
  9. Terumo Medical Corporation $41 1 payment
  10. Qapel Medical Inc $41 1 payment
  11. Other $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,560 13 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,860 11 payments
  3. Food and Beverage $6,887 170 payments
  4. Travel and Lodging $2,849 12 payments
Products named General payments · program years 2019–2025
  1. Pipeline Flow Diversion $17,860 18 payments
  2. SURPASS EVOLVE $6,575 15 payments
  3. SYNCHRO SELECT $5,957 3 payments
  4. EXCELSIOR SL-10 $5,950 2 payments
  5. TARGET $1,556 35 payments
  6. FLOWGATE $1,092 5 payments
  7. 1488, IDEAL EYES $913 3 payments
  8. DAC 044 $675 1 payment
  9. PHIL $600 1 payment
  10. Pipeline Flow Diversion $439 4 payments
  11. Other $4,465 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. MicroVention, Inc. $1,200 1 payment

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$52,779

Medicare's payments for the services billed

Medicare patients

62

Average age 74

Services billed

318

42 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 37%
Ischemic heart disease 29%
Osteoporosis 29%
Depression 27%
Diabetes 24%
Atrial fibrillation 21%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record